deltatrials
Terminated PHASE2 INTERVENTIONAL 1-arm NCT00765102

Trial of Romidepsin and Bortezomib for Multiple Myeloma

A Phase II Trial of Romidepsin and Bortezomib for Multiple Myeloma Patients With Relapsed or Refractory Disease

Sponsor: Celgene

Updated 7 times since 2017 Last updated: Nov 14, 2019 Started: Sep 1, 2008 Primary completion: Mar 1, 2010 Completion: Mar 1, 2010
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

There was a change in the Sponsor's research strategy; safety concerns were not a factor.

This PHASE2 trial investigates Multiple Myeloma and is currently terminated or withdrawn. Celgene leads this study, which shows 7 recorded versions since 2008 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotTerminated~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotTerminated~Jun 2018 – ~Dec 2019 · 18 months · monthly snapshotTerminated~Dec 2019 – ~Jan 2021 · 13 months · monthly snapshotTerminated~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – present · 22 months · monthly snapshotTerminated

Change History

7 versions recorded
  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE2

  4. Dec 2019 — Jan 2021 [monthly]

    Terminated PHASE2

  5. Jun 2018 — Dec 2019 [monthly]

    Terminated PHASE2

Show 2 earlier versions
  1. Feb 2017 — Jun 2018 [monthly]

    Terminated PHASE2

  2. Jan 2017 — Feb 2017 [monthly]

    Terminated PHASE2

    First recorded

Sep 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Celgene
Data source: Celgene

For direct contact, visit the study record on ClinicalTrials.gov .